Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis

NCT02098473 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT02098473
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02098473 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Lead sponsor
Celgene
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2014
Completion date
January 30, 2017
Enrollment
100 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

eosinophilic esophagitis